文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

RUNX1-FPDMM恒河猴模型重现人类表型并预测治愈性基因治疗的挑战

A RUNX1-FPDMM rhesus macaque model reproduces the human phenotype and predicts challenges to curative gene therapies.
PubMed 文献 · Blood · 2023-01-01

研究利用CRISPR/Cas9在RUNX1基因及AAVS1对照位点编辑恒河猴自体造血干/祖细胞(HSPC)并混合移植,追踪等位基因频率。两只动物中RUNX1编辑细胞随时间扩增超过AAVS1编辑细胞,血小板长期低于正常范围,骨髓出现巨核细胞发育异常,CD34+ HSPC体外巨核分化受损且多倍化缺陷显著。结论提示野生型或对照编辑HSPC长期对RUNX1杂合突变HSPC无竞争优势,FPDMM基因校正面临挑战。

要点

  • RUNX1编辑恒河猴HSPC混合移植后随时间扩增超过AAVS1编辑细胞。
  • 长期血小板计数低于正常范围,骨髓出现类似人类FPDMM的巨核细胞发育异常。
  • CD34+ HSPC体外巨核分化受损,多倍化缺陷显著。

核心结论

  • 临床前模型中野生型或对照编辑HSPC长期对RUNX1杂合突变HSPC无竞争优势,提示FPDMM基因校正方法具有挑战性,尤其难以逆转MDS/AML易感和血小板生成缺陷。

研究设计与样本

  • 利用CRISPR/Cas9非同源末端连接编辑RUNX1基因及AAVS1安全港对照位点,构建FPDMM竞争性重建造血模型恒河猴。
  • 移植混合的自体编辑HSPC,追踪血细胞中突变等位基因频率。

主要发现

  • 两只动物中RUNX1编辑细胞随时间扩增超过AAVS1编辑细胞。
  • 血小板计数长期低于正常范围。
  • 骨髓出现类似人类FPDMM的巨核细胞发育异常。
  • CD34+ HSPC体外巨核分化受损,多倍化缺陷显著。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Germ line loss-of-function heterozygous mutations in the RUNX1 gene cause familial platelet disorder with associated myeloid malignancies (FPDMM) characterized by thrombocytopenia and a life-long risk of hematological malignancies. Although gene therapies are being considered as promising therapeutic options, current preclinical models do not recapitulate the human phenotype and are unable to elucidate the relative fitness of mutation-corrected and RUNX1-heterozygous mutant hematopoietic stem and progenitor cells (HSPCs) in vivo long term. We generated a rhesus macaque with an FPDMM competitive repopulation model using CRISPR/Cas9 nonhomologous end joining editing in the RUNX1 gene and the AAVS1 safe-harbor control locus. We transplanted mixed populations of edited autologous HSPCs and tracked mutated allele frequencies in blood cells. In both animals, RUNX1-edited cells expanded over time compared with AAVS1-edited cells. Platelet counts remained below the normal range in the long term. Bone marrows developed megakaryocytic dysplasia similar to human FPDMM, and CD34+ HSPCs showed impaired in vitro megakaryocytic differentiation, with a striking defect in polyploidization. In conclusion, the lack of a competitive advantage for wildtype or control-edited HSPCs over RUNX1 heterozygous-mutated HSPCs long term in our preclinical model suggests that gene correction approaches for FPDMM will be challenging, particularly to reverse myelodysplastic syndrome/ acute myeloid leukemia predisposition and thrombopoietic defects.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Lee BC, Zhou Y, Bresciani E, et al. A RUNX1-FPDMM rhesus macaque model reproduces the human phenotype and predicts challenges to curative gene therapies. Blood. 2023. PMID: 36322931. doi:10.1182/blood.2022018193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。